Reproductive Health

Cyclica Receives a $1.8M Grant from the Bill & Melinda Gates Foundation to Advance the Development of Non-hormonal Contraceptives

Cyclica, a biotech company that is unlocking the protein universe to discover the medicines of tomorrow, is developing new, non-hormonal contraceptives for low-data biological protein targets with support from a grant from the Bill & Melinda Gates Foundation. The CAD$2.4M (USD$1.8M) grant enables Cyclica to apply its validated, AI-enabled drug discovery platform towards the discovery of expanded contraceptive options. To date, research on discovering…

Japanese ARCH Raises $1.65M for Its Fertility Focused, Tech-enabled ‘Torch Clinic’

ARCH, the company behind ‘Torch Clinic’, a tech-enabled company has raised 230M Yen ($1.65M USD) in seed funding from University of Tokyo Edge Capital Partners, XTech Ventures, and ANRI. Since its founding in 2021, ARCH has been working on various digital health services in the area of reproductive and gynecological health (B2C & B2B). The company’s tech-enabled ‘Torch Clinic’ opened earlier this…

Sebela Pharmaceuticals Launches a New Division Dedicated to Women’s Health

Sebela Pharmaceuticals is launching a new division of the company named Sebela Women’s Health along with the appointment of Kelly Culwell, MD, as Head of Research and Development for the division. Bringing more than twenty years’ experience in women’s health across public, private and non-profit organizations, Dr. Culwell joins the team when the company is in the final stages of clinical development of two…

Contraline Adds $7.2M in Funding; Announces First Patients Successfully Implanted in Male Contraceptive Study

Contraline, the company working on developing male contraceptive implants, has announced the first hydrogel-based male contraceptive implants were performed in humans in a clinical trial. These procedures represent a significant milestone for the development of the company’s flagship product, ADAM, a male contraceptive that is long-lasting, non-hormonal, and non-permanent. Four men were implanted with ADAM at Epworth Freemasons Hospital in Melbourne, Australia,…

TMRW Life Sciences Receives FDA Clearance for CryoRobot Select, Its Automated IVF Specimen Storage Solution

TMRW Life Sciences, a fertility technology company modernizing and automating specimen management, has received FDA510(k) clearance for the CryoRobot Select (CRS). TMRW’s CryoRobot Select is the only FDA-cleared automated solution that digitally tracks, monitors and manages frozen eggs and embryos used in IVF. Fully integrated with TMRW’s proprietary ivfOS software, which assigns a unique identifier for each specimen, the CryoRobot Select represents a…

Inception Fertility Partners with Gameto, OTO, Oura & Alife Health on New Research to Advance Reproductive Medicine 

Continuing its mission to lead advancements in reproductive science and medicine, Inception Fertility has partnered with other leading technology companies on four fertility studies with the goal to elevate the patient experience, evolve fertility services, and enhance pregnancy outcomes. Led by Alice Domar, PhD, Chief Compassion Officer at Inception, the clinical research team is designed to give Inception tools to better understand and…

Bayer Receives a Grant from the Bill & Melinda Gates Foundation to Advance Research in Non-Hormonal Contraception

Pharma company Bayer has recently received a grant from the Bill & Melinda Gates Foundation. As part of the grant, the two organizations have each committed more than $12M over four years to co-fund pre-clinical research activities with the goal of providing women globally with an option for non-hormonal contraception. In addition to research co-funding over a four-year period, Bayer will leverage…

VCs For Repro: 100+ VC Firms Take a Stand on Reproductive Rights Ahead of Midterm Elections in the U.S.

“Women’s ability to participate freely and fully in the workforce is essential to the growth, performance and resilience of the U.S. economy and the businesses which comprise it. Their participation is contingent upon access to comprehensive reproductive health services, including contraception and abortion. These services are used by nearly all women – 99 percent have used contraception and 25 percent have had…